A Phase 3 clinical trial, FORT, evaluating Retrophin’s (NASDAQ:RTRX) fosmetpantotenate in patients with pantothenate kinase-associated neurodegeneration (PKAN) failed to demonstrate a treatment effect versus placebo.
On a positive note, the phosphopantothenic acid prodrug was safe and well-tolerated.
PKAN in an inherited neurodegenerative disorder characterized by progressive difficulty with movement, typically starting in childhood.
Management will host a conference call this morning at 8:30 am ET to discuss the data.
Shares are down 25% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.